These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9498179)

  • 21. Pharmacotherapy of panic disorder.
    Shelton RC
    Hosp Community Psychiatry; 1993 Aug; 44(8):725-6. PubMed ID: 8104161
    [No Abstract]   [Full Text] [Related]  

  • 22. Benzodiazepines and anxiety sensitivity in panic disorder.
    Fava GA; Grandi S; Belluardo P; Savron G; Raffi AR; Conti S; Saviotti FM
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Nov; 18(7):1163-8. PubMed ID: 7846286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up.
    de Beurs E; van Balkom AJ; Van Dyck R; Lange A
    Acta Psychiatr Scand; 1999 Jan; 99(1):59-67. PubMed ID: 10066008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Panic disorder].
    Heinzl S
    Med Monatsschr Pharm; 1996 Mar; 19(3):79-80. PubMed ID: 8868966
    [No Abstract]   [Full Text] [Related]  

  • 25. Mechanisms of change in cognitive behaviour therapy for panic disorder: the role of panic self-efficacy and catastrophic misinterpretations.
    Fentz HN; Hoffart A; Jensen MB; Arendt M; O'Toole MS; Rosenberg NK; Hougaard E
    Behav Res Ther; 2013 Sep; 51(9):579-87. PubMed ID: 23872700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life in social anxiety disorder compared with panic disorder and the general population.
    Simon NM; Otto MW; Korbly NB; Peters PM; Nicolaou DC; Pollack MH
    Psychiatr Serv; 2002 Jun; 53(6):714-8. PubMed ID: 12045308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin selectivity for obsessive compulsive and panic disorders.
    Montgomery SA; Bullock T; Fineberg N
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):30-5. PubMed ID: 1931935
    [No Abstract]   [Full Text] [Related]  

  • 28. Compulsive buying and binge eating disorder--a case vignettes.
    Marcinko D; Bolanca M; Rudan V
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1542-4. PubMed ID: 16815617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Panic disorder and agoraphobia: what is effective?].
    Bandelow B; Sievert K; Röthemeyer M; Hajak G; Broocks A; Rüther E
    Fortschr Neurol Psychiatr; 1995 Nov; 63(11):451-64. PubMed ID: 8575719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A journey through anxiety and depression.
    Stansbury W
    Can Nurse; 2008 Oct; 104(8):10-1. PubMed ID: 18979859
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical effects of fluvoxamine on panic symptomatology.
    Pols H; Zandergen J; de Loof C; Fernandez I; Griez E
    Acta Psychiatr Belg; 1993; 93(3):169-77. PubMed ID: 8030430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acute anxiety and panic attack].
    Thomas G; Genest P; Walter M
    Rev Prat; 2008 Sep; 58(14):1597-600. PubMed ID: 18839691
    [No Abstract]   [Full Text] [Related]  

  • 33. A kind of D-amino acid oxidase inhibitor, sodium benzoate, might relieve panic symptoms in a first-episode, drug-naïve panic-disorder patient.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):E7-8. PubMed ID: 23686042
    [No Abstract]   [Full Text] [Related]  

  • 34. Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series.
    Otto MW; Pollack MH; Penava SJ; Zucker BG
    Behav Res Ther; 1999 Aug; 37(8):763-70. PubMed ID: 10452176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of well being in panic disorder: the assessment of psychiatric and general disability.
    Rubin HC; Rapaport MH; Levine B; Gladsjo JK; Rabin A; Auerbach M; Judd LL; Kaplan R
    J Affect Disord; 2000; 57(1-3):217-21. PubMed ID: 10708834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Paroxysmal neurological manifestations disclosing panic attacks].
    Petiau C; Hirsch E; Peretti S; Sellal F; Hammouti A; Danion JM; Marescaux C
    Rev Neurol (Paris); 1992; 148(8-9):555-9. PubMed ID: 1362998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.
    Ueda N; Terao T; Ohmori O; Nakamura J
    Hum Psychopharmacol; 2003 Aug; 18(6):477-8. PubMed ID: 12923827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behavior therapy.
    Otto MW; Hong JJ; Safren SA
    Curr Pharm Des; 2002; 8(1):75-80. PubMed ID: 11812251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationships between symptoms and quality of life over the course of cognitive-behavioral therapy for panic disorder in Japan.
    Ogawa S; Kondo M; Okazaki J; Imai R; Ino K; Furukawa TA; Akechi T
    Asia Pac Psychiatry; 2017 Jun; 9(2):. PubMed ID: 27481539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Booster Sessions after Cognitive-Behavioural Group Therapy for Panic Disorder: Impact on Resilience, Coping, and Quality of Life.
    Wesner AC; Gomes JB; Detzel T; Guimarães LS; Heldt E
    Behav Cogn Psychother; 2015 Sep; 43(5):513-25. PubMed ID: 24914489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.